McNamara Robert

SEC source: 0001387652-26-000001 · ownership.xml · derivative · entry 2

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,133

Underlying: Common Stock · 16,133 shares

Expires 2036-01-20

F3 · derivative.exercise_price: On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

SEC source: 0001387652-26-000001 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,985

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0000950170-25-112234 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,771

F1 · balance_after: Includes unvested RSUs

SEC source: 0000950170-25-110499 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,771

SEC source: 0000950170-25-036355 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,749

F1 · balance_after: Includes unvested RSUs

SEC source: 0000950170-25-024211 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,749

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.89 to $10.19. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares of Common Stock purchased at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · balance_after: Includes unvested RSUs

SEC source: 0000950170-25-082439 · ownership.xml · derivative · entry 2

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,295

Underlying: Common Stock · 4,295 shares

Expires 2035-01-21

F3 · derivative.exercise_price: On January 6, 2025, the Board of Directors approved a grant of 4,295 options to acquire 4,295 shares of Common Stock to each of its non-executive directors, with a grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

SEC source: 0000950170-25-082439 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,771

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 21, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0001562180-24-007707 · primarydocument.xml · derivative · entry 4

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2028-12-06

F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

SEC source: 0001562180-24-007707 · primarydocument.xml · derivative · entry 3

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,333 shares

Expires 2029-06-27

F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

SEC source: 0001562180-24-007707 · primarydocument.xml · derivative · entry 2

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2029-08-22

F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

SEC source: 0001562180-24-007707 · primarydocument.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration").

F1 · price: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration").

SEC source: 0000950170-24-099134 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,749

SEC source: 0001235802-24-000069 · primary_doc.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 754,151

F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2025, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 307,342 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

SEC source: 0000950170-24-070096 · ownership.xml · derivative · entry 2

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,943

Underlying: Common Stock · 3,943 shares

Expires 2034-06-05

SEC source: 0000950170-24-070096 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,749

F1 · price: Represents an award of RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0001850902-24-000007 · edgardoc.xml · derivative · entry 4

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 31,959 shares

Expires 2031-06-24

F5 · shares: Forfeiture of vested stock options after the expiration of the three-month exercise period following the effective date of the Reporting Person's resignation from the Board of Directors.

F4 · derivative.exercise_date: On June 24, 2021, the Reporting Person was granted 44,251 stock options. 1/3rd of the original number of shares subject to the option shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in equal monthly installments thereafter over 24 months.

SEC source: 0001850902-24-000007 · edgardoc.xml · derivative · entry 3

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,959

Underlying: Common Stock · 12,292 shares

Expires 2031-06-24

F3 · shares: Forfeiture of unvested stock options upon the effective date of the Reporting Person's resignation from the Board of Directors.

F4 · derivative.exercise_date: On June 24, 2021, the Reporting Person was granted 44,251 stock options. 1/3rd of the original number of shares subject to the option shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in equal monthly installments thereafter over 24 months.

SEC source: 0001850902-24-000007 · edgardoc.xml · nonDerivative · entry 2

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,357

F2 · shares: Reflects the forfeiture of 18,815 restricted stock units in connection with the Reporting Person's resignation from the Board of Directors of Alpha Teknova, Inc., effective August 31, 2023.

SEC source: 0001235802-23-000092 · primary_doc.xml · derivative · entry 2

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,230

Underlying: Common Stock · 28,230 shares

Expires 2033-08-15

F3 · derivative.exercise_date: This option vests on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-23-000092 · primary_doc.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 591,989

F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 145,180 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001562180-23-005530 · primarydocument.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,861

SEC source: 0001209191-23-035437 · doc4.xml · derivative · entry 4

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,646

Underlying: Common Stock · 2,646 shares

Expires 2033-06-06

F1 · shares: The reporting person may elect to acquire the Issuer's CHESS Depositary Interests ("CDIs") in place of common stock upon vesting of a Restricted Stock Unit ("RSU") or exercise of a Stock Option. CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of common stock and have all the rights and privileges of common stock.

F6 · derivative.exercise_date: These Stock Options vest on the date 12 months following the grant date.

SEC source: 0001209191-23-035437 · doc4.xml · derivative · entry 3

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,446

Underlying: Common Stock · 4,446 shares

Expires 2033-06-06

F1 · shares: The reporting person may elect to acquire the Issuer's CHESS Depositary Interests ("CDIs") in place of common stock upon vesting of a Restricted Stock Unit ("RSU") or exercise of a Stock Option. CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of common stock and have all the rights and privileges of common stock.

F5 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning on the date 12 months following the grant date.

SEC source: 0001209191-23-035437 · doc4.xml · nonDerivative · entry 2

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,549

F1 · shares: The reporting person may elect to acquire the Issuer's CHESS Depositary Interests ("CDIs") in place of common stock upon vesting of a Restricted Stock Unit ("RSU") or exercise of a Stock Option. CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of common stock and have all the rights and privileges of common stock.

F4 · price: Represents an award of RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date.

F3 · balance_after: Includes unvested RSUs.

SEC source: 0001209191-23-035437 · doc4.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,374

F1 · shares: The reporting person may elect to acquire the Issuer's CHESS Depositary Interests ("CDIs") in place of common stock upon vesting of a Restricted Stock Unit ("RSU") or exercise of a Stock Option. CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of common stock and have all the rights and privileges of common stock.

F2 · price: Represents an award of RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments beginning on the date 12 months following the grant date.

F3 · balance_after: Includes unvested RSUs.

SEC source: 0001850902-24-000007 · edgardoc.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,172

F1 · shares: Represents restricted stock units granted on June 2, 2023. Shares subject to the award vest on the first anniversary of the grant date.

SEC source: 0001562180-22-006263 · primarydocument.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,861

SEC source: 0001235802-22-000098 · primary_doc.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 446,809

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and vest and become issuable on August 15, 2023, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 215,415 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

SEC source: 0001850902-22-000019 · edgardoc.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,357

F1 · shares: Represents restricted stock units granted on June 2, 2022. Shares subject to the award vest on the first anniversary of the grant date.

SEC source: 0001562180-21-006823 · primarydocument.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,761

SEC source: 0001235802-21-000105 · primary_doc.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 231,394

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and vest and become issuable on August 15, 2022, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 143,436 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

SEC source: 0000899243-21-026324 · doc4.xml · derivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,251

Underlying: Common Stock · 44,251 shares

Expires 2031-06-24

F1 · derivative.exercise_date: 1/3rd of the original number of shares subject to the option shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in equal monthly installments thereafter over 24 months.

SEC source: 0001235802-20-000004 · primary_doc.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,057

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and will vest and become issuable with respect 58,098 shares on February 15, 2021 and with respect to 58,099 shares on February 15, 2022, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes (i) 116,197 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the reporting person remaining a director of Xtant through the vesting date; (ii) 9,027 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date, and (iii) 10,417 shares issued as part of a restricted stock award granted under the Amended and Restated Xtant Equity Incentive Plan, which shares are subject to forfeiture until vested.

SEC source: 0001235802-19-000123 · primary_doc.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,860

F1 · shares: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and will vest and become issuable on February 15, 2020, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 9,027 shares to be issued upon vesting pursuant to restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date, and 10,417 shares issued as part of a restricted stock award granted under the Amended and Restated Xtant Equity Incentive Plan, which shares are subject to forfeiture until vested.

SEC source: 0001144204-18-025318 · tv493135_4.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,833

F1 · shares: The common stock vests as follows: (i) 10,416 shares of common stock vests on February 15, 2019, and (ii) 10,417 shares of common stock vests of February 15, 2020.